June 2010: Merrion Pharmaceuticals to present at UBS 2010 Global Specialty Pharmaceuticals
Conference in London
May 2010: Merrion Pharmaceuticals Appoints Dr. Hing Kin Chan as Chief Business Officer
May 2010: Merrion Pharmaceuticals is issued a key US patent for Orazol™
Merrion Pharmaceuticals offers unique prescription pharmaceutical products to meet key unmet needs in healthcare. Merrion is focused on delivering innovation, primarily by converting injection only medicines into tablets / capsules and inventing optimum products reaching full commercial potential.
Merrion both develops its own unique products and partners with pharmaceutical companies to develop products of strategic importance.
Merrion Pharmaceutical's patented drug delivery technology greatly improves absorption and variability of poorly absorbed drugs.
These new products can provide substantial benefits in enhanced drug efficacy, improved safety, reduced toxicity and side effect profile, better health economics, patient experience and quality of life. They can also command branded pricing on the market and allow expansion of the market or the product's indications.
July 2010: Merrion Pharmaceuticals new facility is granted license to manufacture by Irish Medicines Board
Merrion Pharmaceuticals plc (ESM:MERR), a pharmaceutical development company, today announces that their new state of the art facility in Citywest has been licensed, under the EU Clinical Directive for Investigational medicinal products, by the Irish Medicines Board (IMB).